Business Context and Reporting Period
Company: Lineage Cell Therapeutics, Inc. (LCTX)
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2026
Event: Filing of a Prospectus Supplement to update a shelf registration statement (Form S-3) regarding an At-The-Market (ATM) equity offering program.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or margins. The document focuses exclusively on capital raising activities.
- Proposed Offering Size: Up to $60,000,000 in aggregate offering price for common shares.
- Previous Sales under Program: $22,583,663.82 in aggregate gross sales price sold pursuant to prior supplements and the base prospectus.
- Underwriter: B. Riley Securities, Inc.
Material Changes
The filing represents a material update to the Company's capital raising capacity under its existing Sales Agreement dated March 22, 2024. The new Prospectus Supplement supersedes prior supplements dated November 12, 2025, and May 14, 2024, to authorize the sale of an additional $60 million in shares, distinct from the amounts previously sold.
Guidance, Outlook, and Risks
Management Commentary: The filing is a procedural disclosure required by the SEC to enable the continued sale of shares under the ATM program. It does not include forward-looking guidance, operational outlook, or management commentary on business strategy.
Risks and Contingencies: The document notes that the report does not constitute an offer to sell shares in any jurisdiction where such an offer would be unlawful prior to registration. It references a legal opinion regarding the legality of the shares.
Investor Verification Checklist
- Verify the current market price of LCTX shares to assess the potential dilution impact of the $60 million offering.
- Review the most recent 10-K or 10-Q filings to understand the Company's current cash position and liquidity needs driving this capital raise.
- Confirm the total number of shares authorized for sale under the updated ATM program versus the shares already sold ($22.58 million).
- Check for any concurrent press releases detailing the specific use of proceeds from this offering.